Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tosedostat + Erlotinib in Advanced NSCLC
NCT00522938Phase 2Terminated
- Sponsor
- Chroma Therapeutics
- Start
- Dec 2007
- Primary completion
- Feb 2008
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tosedostat in non-small cell lung cancer (NSCLC), sponsored by Chroma Therapeutics. Primary endpoints: Maximum Tolerated Dose at Cycle 1 and Objective Tumor Response Rate. Started Dec 2007; status: terminated.
02
Drugs
tosedostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00522938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522938.